January 22 – Year-end report 2024
Alligator hosted a webinar on Wednesday, January 22, at 3 p.m. CET for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the Year-end report, which was followed by a Q&A session.
The call was held in English and can be requested through the link below.
LATEST NEWS
Alligator Bioscience Announces Publication of Clinical Data for ATOR-1017 (evunzekibart) in the Journal for ImmunoTherapy of Cancer
Publication validates encouraging clinical safety and tolerability in this first-in-human trial Data show early signs of clinical efficacy i …
The subscription period in Alligator Bioscience’s rights issue begins today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, …
Alligator Bioscience Reports Incremental Overall Survival Benefit of mitazalimab combined with mFOLFIRINOX based on Literature-based Indirect Comparison of Outcomes
Indirect Comparison shows significant improvement of OS of mitazalimab + mFOLFIRINOX, compared to known FOLFIRINOX and NALIRIFOX outcomes Th …